Approval · Notice of Compliance 1066 · 2000
NIMBEX: Notice of Compliance 1066
Issued March 21, 2000
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 1066
- Date
- March 21, 2000
- Company
- Glaxo Wellcome Inc.Mississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Product monograph update - for use during coronary artery bypass graft surgery
- Therapeutic class
- Non-depolarizing skeletal neuromuscular blocking agent
Products in this notice
Medicinal ingredients
- CISATRACURIUM BESYLATE 2 MG per ML
- CISATRACURIUM BESYLATE 10 MG per ML